NASDAQ:BOLDAudentes Therapeutics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $59.97 0.00 (0.00 %) (As of 01/15/2020) Add Compare Share Today's Range$59.97Now: $59.97▼$59.9750-Day Range$59.97MA: $59.97▼$59.9752-Week Range$22.00Now: $59.97▼$60.00VolumeN/AAverage Volume1.50 million shsMarket Capitalization$2.77 billionP/E RatioN/ADividend YieldN/ABeta2.18 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.Read More Beat the Market (BTM) Rank™ 1.1 Analyst's Opinion Consensus RatingAudentes Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 2 buy ratings, 13 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.75, Audentes Therapeutics has a potential downside of 15.4% from its current price of $59.97.Amount of Analyst CoverageAudentes Therapeutics has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesAudentes Therapeutics has received 467 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAudentes Therapeutics has received 419 “underperform” votes. (Add your “underperform” vote.)Community SentimentAudentes Therapeutics has received 52.71% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote “Outperform” if you believe BOLD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BOLD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAudentes Therapeutics does not currently pay a dividend.Dividend GrowthAudentes Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Audentes Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Audentes Therapeutics is held by insiders.Percentage Held by Institutions96.33% of the stock of Audentes Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Audentes Therapeutics are expected to decrease in the coming year, from ($4.13) to ($4.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Audentes Therapeutics is -17.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Audentes Therapeutics is -17.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.93 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BOLD Previous Symbol CUSIPN/A CIK1628738 Webwww.audentestx.com Phone415-818-1001Debt Debt-to-Equity RatioN/A Current Ratio12.80 Quick Ratio12.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($7.48) per share Price / Book-8.02Profitability EPS (Most Recent Fiscal Year)($3.40) Net Income$-128,820,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-38.00%Miscellaneous Employees207 Outstanding Shares46,272,000Market Cap$2.77 billion Next Earnings DateN/A OptionableOptionable Receive BOLD News and Ratings via Email Sign-up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter. Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Audentes Therapeutics? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 13 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Audentes Therapeutics. How were Audentes Therapeutics' earnings last quarter? Audentes Therapeutics Inc (NASDAQ:BOLD) posted its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($1.00) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.07) by $0.07. During the same quarter in the previous year, the business posted ($0.97) earnings per share. View Audentes Therapeutics' earnings history. What price target have analysts set for BOLD? 15 brokers have issued 12 month price objectives for Audentes Therapeutics' stock. Their forecasts range from $10.00 to $60.00. On average, they anticipate Audentes Therapeutics' share price to reach $50.75 in the next twelve months. This suggests that the stock has a possible downside of 15.4%. View analysts' price targets for Audentes Therapeutics. Has Audentes Therapeutics been receiving favorable news coverage? Press coverage about BOLD stock has been trending positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Audentes Therapeutics earned a news impact score of 2.6 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutAudentes Therapeutics. Who are some of Audentes Therapeutics' key competitors? Some companies that are related to Audentes Therapeutics include BIO-TECHNE (TECH), argenx (ARGX), Qiagen (QGEN), Repligen (RGEN), Allogene Therapeutics (ALLO), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), bluebird bio (BLUE) and Halozyme Therapeutics (HALO). View all competitors. What other stocks do shareholders of Audentes Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Crispr Therapeutics (CRSP), Energy Transfer LP Unit (ET), Gilead Sciences (GILD), Clovis Oncology (CLVS), Intel (INTC), AbbVie (ABBV), Exelixis (EXEL), Ford Motor (F), Global Blood Therapeutics (GBT) and Myriad Genetics (MYGN). Who are Audentes Therapeutics' key executives? Audentes Therapeutics' management team includes the following people: Mr. Matthew R. Patterson, Co-Founder, Chairman & CEO (Age 47)Ms. Natalie C. Holles, Pres & COO (Age 46)Mr. Thomas P. Soloway, Exec. VP & CFO (Age 52)Dr. John T. Gray, Sr. VP & Chief Scientific Officer (Age 56)Mr. Andrew H. Chang, Director of Investor Relations When did Audentes Therapeutics IPO? (BOLD) raised $75 million in an initial public offering on Wednesday, July 20th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Audentes Therapeutics' stock symbol? Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD." What is Audentes Therapeutics' stock price today? One share of BOLD stock can currently be purchased for approximately $59.97. How big of a company is Audentes Therapeutics? Audentes Therapeutics has a market capitalization of $2.77 billion. The biotechnology company earns $-128,820,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 207 workers across the globe. What is Audentes Therapeutics' official website? The official website for Audentes Therapeutics is www.audentestx.com. How can I contact Audentes Therapeutics? Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
